MacroGenics Stock
MacroGenics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Eric Risser
- Employees
- 293
- Market cap
- $207 M
- IPO
- 10/10/2013
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and…
MacroGenics stock: price history
1D
-3.6%
1W
-13.1%
1M
-20.3%
6M
-6.1%
YTD
+101.9%
1Y
+92.3%
2Y
-21.1%
5Y
-83.5%
10Y
-87.3%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~173% stronger price swings than usual
MacroGenics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 24/08/2026.
Ask the agents about MacroGenics
Analyst assessment of MacroGenics
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
12
BUY
9
HOLD
1
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 17/08/2026
MacroGenics stock metrics
P/E
-14.77
P/B
4.82
EV/EBITDA
-1.57
RETURN ON EQUITY
45.5%
NET MARGIN
59.4%
DEBT/EQUITY
0.82
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.6%
FLOAT SHARES
56,407,153
AVG. DAILY VOLUME (30D)
582,221
Insider transactions (SEC)
Bonvini Ezio
Peters Jeffrey Stuart
Bonvini Ezio
HEIDEN WILLIAM K
Liu Margaret
Attention
Price since yesterday: -3.6%
Search (Google Trends)
Institutional holders
Comparable stocks
Frequently asked questions about MacroGenics stock
What does MacroGenics do?
MacroGenics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Eric Risser, the company employs around 293 people.
The IPO was on 10/10/2013; the stock trades on NASDAQ under the ticker MGNX.
What do analysts say about MacroGenics stock?
22 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does MacroGenics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 173% stronger than usual.
Does MacroGenics pay a dividend?
No, MacroGenics currently does not pay a dividend.
Which stocks are comparable to MacroGenics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MacroGenics stock analyzed?
Clicking "Analyze stock" lets five strategies assess MacroGenics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.